Johns Hopkins-sponsored HCC trial of Nivolumab plus Relatlimab posts results, now not recruiting

One registry update this week concerns a Bristol-Myers Squibb-collaborated study in hepatocellular carcinoma.

• This is a Phase 1 trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins with Bristol-Myers Squibb as collaborator, testing neoadjuvant and adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with potentially resectable hepatocellular carcinoma to assess safety and feasibility.¹ The study's status is now active, not recruiting, with an actual enrollment completion and primary completion date of 2025-09-02, and results first posted on 2026-10-28.¹ Enrollment reached 31 participants (actual).¹ The primary outcome measured the number of patients precluded from surgery due to a treatment-related adverse event within 60 days of the last dose of neoadjuvant treatment.¹